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One half of cortical thymoma patients develop myasthenia gravis (MG), while 15% of MG patients have thymomas. MG is a
neuromuscular junction disease caused in 85% of the cases by acetylcholine receptor (AChR) antibodies. Titin and ryanodine
receptor (RyR) antibodies are found in 95% of thymoma MG and 50% of late-onset MG (MG onset ≥50 years), are associated
withseveredisease,andmaypredictthymomaMGoutcome.NonlimbsymptomproﬁleatMGonsetwithbulbar,ocular,neck,and
respiratory symptoms should raise the suspicion about the presence of thymoma in MG. The presence of titin and RyR antibodies
in an MG patient younger than 60 years strongly suggests a thymoma, while their absence at any age strongly excludes thymoma.
Thymoma should be removed surgically. Prethymectomy plasmapheresis/iv-IgG should be considered before thymectomy. The
pharmacological treatment does not diﬀer from nonthymoma MG, except for tacrolimus which is an option in diﬃcult thymoma
and nonthymoma MG cases with RyR antibodies.
1. Thymoma inMyasthenia Gravis
Thymomas in myasthenia gravis (MG) are neoplasms de-
rived from thymic epithelial cells, and are usually of the
cortical subtype (WHO type B) [1]. 50% of thymoma pa-
tients develop MG (hereafter referred to as thymoma MG
in this paper) [2, 3]. Cortical thymomas usually have some
morphological similarities with thymic cortex; they share the
capacitytopropagatethematurationofimmaturenaiveCD4
T cells and export mature naive T cells into the periphery.
Thymomas lacking this ability do not induce MG [4].
Thymomaswithhistologicalsimilaritiestomedullarythymic
tissue or thymomas lacking developing T cells are seldom
associated with MG [4]. Other thymoma characteristics that
can cause reduced self-tolerance include defective epithelial
expression of the autoimmune regulator (AIRE) gene and/or
of major histocompatibility complex class II molecules, ab-
senceofmyoidcells,failuretogenerateFOXP3(+)regulatory
Tcells,andgeneticpolymorphismsaﬀectingT-cellsignalling
[5].
Histologically, thymomas are epithelial neoplastic cells
surrounded by maturing T cells. The epithelial cells are capa-
ble of expressing epitopes cross-reactive with skeletal muscle
proteins, such as acetylcholine receptor (AChR), titin, and
ryanodinereceptor(RyR)[6,7].Themuscle-likeepitopesare
presented to T cells together with costimulatory molecules
[7].AutoreactiveTcellsspeciﬁcforAChRandtitinarefound
both in thymomas and in thymoma MG patients’ sera [8].
Thymoma epithelial cells present AChR peptides to T-cell
lines in thymoma MG patients, facilitating intrathymic im-
munization [9].
The patient’s genetic proﬁle and the thymic ability to
export autoreactive T cells are equally important in develop-
ing MG. MG has a genetic association to HLA-DR3 or ances-
tral haplotype 8.1 in early-onset MG (MG onset before age
50 years) with thymic hyperplasia and several weaker asso-
ciations to polymorphisms in immunoregulatory genes such
as FcγR, TNF-α/β,G M - p h e n o typ e s ,C T L A - 4[ 10], HLA, and
PTPN22 ∗ R620W [11]. The chance of having a thymoma
increases with the number of thymoma-associated polymor-
phisms in an MG patient, indicating that thymoma MG is a
polygenic disease and that thymoma patients with a particu-
lar genetic proﬁle run higher risk of developing MG [11].
2. Thymoma MG
MG is a neuromuscular junction disease characterized by
muscular weakness and fatigability, caused in 85% of the2 Autoimmune Diseases
Table 1: The occurrence of the various muscle autoantibodies (ab) in the diﬀerent subgroups of MG [13].
MG subgroup AChR ab MuSK ab Titin ab RyR ab
Early onset (non
MuSK nonthymoma) Positive in all patients Negative in all patients Positive in 10% of the
patients
Negative in all
patients
Late onset
(non-MuSK
nonthymoma)
Positive in all patients Negative in all patients Positive in 58% of the
patients
Positive in 14% of the
patients
MuSK positive
(regardless onset age)
Negative in all
patients Positive in all patients No information
available
No information
available
Seronegative
(regardless onset age)
Negative in all
patients Negative in all patients Negative in all
patients
Negative in all
patients
Thymoma (regardless
of onset age) Positive in all patients May occur in some patients Positive in 95% of the
patients
Positive in 70% of the
patients
cases by AChR antibodies [12]. When MG occurs together
with a thymoma, MG is a paraneoplastic disease caused by
the presence of the thymoma. Thymoma MG accounts for
around 15% of all MG cases [13].
The immune response against an epitope expressed on
thymomacellsspillsovertoneuromuscularjunctioncompo-
nents sharing the same epitope [14]. In thymoma MG, epi-
topes are shared between the thymoma and muscle proteins.
3. AntibodiesinThymoma MG
AChR antibodies are the main cause of muscle weakness in
thymoma MG [15]. Additional non-AChR muscle autoanti-
bodies reacting with striated muscle titin and RyR antigens
are found in up to 95% of MG patients with a thymoma and
in 50% of late-onset MG patients (MG onset at age of 50
years or later) [16]. These antibodies are usually associated
with more severe MG [13, 17–19]. Striational antibodies
demonstrated in immunoﬂuorescence are largely made up
of titin antibodies [20].
Titin is the largest known protein, with a molecular mass
of 3000kD stretching throughout the sarcomere, providing
a direct link between mechanical muscle strain and muscle
gene activation [21]. Myositis and myopathy with muscle at-
rophy are seen in some thymoma MG patients [22]. Sera
from MG patients also induce degenerative changes in mus-
cle cell cultures where both apoptosis and necrosis are impli-
cated [23].
The RyR is the calcium channel of the sarcoplasmic ret-
iculum (SR). Upon opening, the RyR releases Ca2+ into the
sarcoplasm resulting in muscle contraction. In vitro, RyR
antibodies can inhibit Ca2+ release from the SR [24]. There is
also a rat model with thymoma and MG with RyR antibodies
but no AChR antibodies, indicating that RyR antibodies
may cause MG symptoms irrespective of AChR antibodies
[25]. There are also several reports of excitation-contraction
coupling defects in thymoma MG [26].
4.Recognizing the ClinicalandSerological
Pattern of Thymoma MG
MG patients with RyR antibodies are characterized by fre-
quent involvement of bulbar, respiratory, and neck muscles
atMGonsetandamoreseveredisease.NeckweaknessatMG
onset is a distinctive feature of patients with RyR antibodies,
while respiratory symptoms are also found in patients with
titin antibodies with and without RyR antibodies. Limb
involvement with few or no bulbar signs is typical at MG
onset in RyR-antibody-negative MG [27]. Since many thy-
moma MG patients have RyR antibodies, neck weakness and
nonlimb bulbar distribution of MG symptoms are initial
characteristic features associated with thymoma MG. Such
symptom distribution should always raise the suspicion
about the presence of a thymoma in an MG patient.
Thymoma MG is equally frequent in males and females
and occurs at any age with a peak onset around 50 years [28].
Thymoma MG and late-onset MG share similar serological
proﬁle with high prevalence of titin and RyR antibodies and
lower AChR antibody concentrations compared to early-
o n s e tM G[ 29]. About 95% and 70% of thymoma MG
patientshavetitinandRyRantibodies, respectively(Table 1).
Around 58% and 14% of late onset MG patients have titin
and RyR antibodies, respectively (Table 1)[ 13].
Late MG onset age, similar serological proﬁle, favorable
pharmacological treatment response, severe MG, frequent
use of immunosuppressive drugs, and the occurrence of
MG related mortality are common features among thymoma
MG and late-onset MG patients [29]. This proﬁle diﬀers
from early-onset MG [30], that has higher AChR anti-
body concentrations, almost no titin or RyR antibodies, low
need for immunosuppressive drugs, less severe MG, very low
MG mortality rates, and a favorable thymectomy outcome
[29].
Thymoma MG tends to be more severe than early-onset
nonthymoma MG [29]. In one study, MG patients with thy-
moma or thymic atrophy (i.e., chieﬂy late-onset MG) had
worse prognosis than MG patients with thymic hyperplasia
(i.e., early-onset MG) [31]. The presence of a thymoma per
se does not give a more severe MG. Thymoma MG patients
and age-matched nonthymoma MG patients share similar
MG long-term prognosis [19]. The presence of titin and RyR
antibodiesisassociatedwithmoreseverediseaseinthymoma
MG and in late-onset MG [29]. The AChR antibody serum
concentration does not correlate with MG severity, mainly
because of individual variations in AChR epitope speciﬁcity
[32].Autoimmune Diseases 3
5. Verifyingthe Diagnosisof Thymoma MG
The diagnosis of MG is based on clinical disease history and
typical clinical ﬁndings. MG can be conﬁrmed pharmaco-
logically by edrophonium (Tensilon) test which is positive
in 90% of MG patients, giving an immediate but transitory
improvement of MG signs [33]. The diagnosis of MG
should be conﬁrmed by the detection of AChR antibodies,
present in most MG cases. These antibodies are present in
virtually all patients with a thymoma [29]. In two thirds
of MG patients, failure of neuromuscular transmission in
leads to decremental response to repetitive nerve stimulation
by electromyographical (EMG) examination [34]. Increased
jitter on single-ﬁber EMG is even more sensitive than repet-
itive nerve stimulation when performed on aﬀected muscles
[34].
In addition to MG, a thymoma should be demonstrated
in order to fulﬁll the criteria of thymoma MG diagnosis. The
diagnosis of a thymoma in MG is ﬁnally established by his-
topathological examination postsurgery. Titin and RyR anti-
bodies and radiological examination of the anterior medias-
tinumsharesimilarsensitivityforthepresenceofathymoma
in MG [29, 35, 36]. However, the presence of titin and RyR
antibodies in a MG patient younger than 60 years strongly
suggests a thymoma, while the absence of such antibodies at
any age strongly excludes thymoma [13, 37]. Retesting for
these antibodies and a new radiological examination should
always be considered whenever clinical deterioration is seen
over time, to minimize the risk of a previously undetected
thymoma in a MG patient.
6.SurgicalTreatment of Thymoma MG
When the diagnosis of a thymoma in a MG patient is
established, the neoplasm should be removed surgically,
and it is crucial to ensure radical excision of the neoplasm.
Thymectomy can be performed transternally or through a
video-assisted thoracoscopic approach, usually with similar
outcome [38]. Radical excision of a thymoma does in most
cases cure the thymic neoplasia, but patients will continue to
suﬀer from MG after thymectomy, emphasizing the need of
continuing followup and pharmacological treatment. When
the thymoma invades the pleura or the pericardium, radical
excision will not be possible and further oncological treat-
ment is necessary. Presurgery plasmapheresis or intravenous
infusion of immunoglobulin (iv-IgG) removes a great deal
of circulating pathogenic antibodies [36]. In our department
we give plasmapheresis or iv-IgG treatment to all patients
with thymoma MG prior to thymectomy, to minimize the
risk of postthymectomy MG exacerbation and myasthenic
crisis. This practice varies however from department to
another, and there is no consensus on this issue. Iv-IgG
should be considered as ﬁrst choice in patients at high risk
of developing cardiopulmonary failure secondary to ﬂuid
overload caused by plasmapheresis [39]. MG outcome after
thymectomy is generally less favorable in patients older than
45 years (i.e., mostly late-onset and thymoma MG patients)
[40].
7. Treatment of MG Crisisin Thymoma MG
Plasmapheresis and immunoglobulin treatments are also
indicated in severe cases of thymoma MG regardless of thy-
mectomy, such as in MG crisis and in severe MG cases with
poor response to standard pharmacological treatment [41].
Parallel to plasmapheresis and immunoglobulin treatment,
the pharmacological treatment should be intensiﬁed in these
patients as explained in the next chapter.
8. PharmacologicalTreatmentofThymomaMG
The ﬁrst pharmacological choice in the treatment of thy-
moma MG is acetylcholinesterase inhibitors. The second
choice is immunosuppressive drugs whenever additional
pharmacological treatment is needed before or after thymec-
tomy. Several immunosuppressive drugs are available, such
as corticosteroids, azathioprine, cyclophosphamide, cyclos-
porine, methotrexate, mycophenolate mofetil, rituximab,
and tacrolimus. Steroids such as prednisolone are frequently
given on alternate days, by gradually raising the dose to 60–
80mg initially and then with slowly tapering to 20mg or
lower. If long-term treatment with steroids is regarded nec-
essary,nonsteroidimmunosuppressantssuchasazathioprine
should be introduced in addition (usually 100–150mg a
day). While the steroid eﬀect appears rapidly, the clinical ef-
fect of other immunosuppressants may take a few weeks to
several months to develop [29]. Overall, about 80% of MG
patients and 95% of thymoma MG patients need immuno-
suppressive drug treatment for more than one year [42].
Tacrolimus, which is an immunosuppressant and en-
hancer of RyR-related sarcoplasmic calcium release, may be
especially beneﬁcial in MG patients with RyR antibodies that
in theory might block the RyR interfering with its function.
Since most patients with thymoma MG have RyR antibodies,
tacrolimus may act speciﬁcally in these patients. It may have
ap u r e l ys y m p t o m a t i ce ﬀect in addition to its immunosup-
pressive impact [40]. Tacrolimus has demonstrated favorable
eﬀects in the treatment of MG, both as monotherapy and
as add-on to prednisolone [43, 44]. Patients should undergo
a thorough cardiological investigation prior to commencing
tacrolimus treatment.
Long-term observation of thymoma MG and age-
matched nonthymoma MG patients showed no diﬀerence
in MG severity over time, and both groups improved to the
same degree after MG diagnosis as a result of pharmacolog-
ical treatment and thymectomy. The need for immunosup-
pressive treatment in the two groups was similarly high. A
thymoma that has been completely removed surgically does
not necessarily mean worse MG prognosis in thymoma MG
[19].
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